These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27062182)

  • 41. Hepatocellular carcinoma and other liver disease among Greenlanders chronically infected with hepatitis B virus: a population-based study.
    Børresen ML; Koch A; Biggar RJ; Andersson M; Wohlfahrt J; Ladefoged K; Melbye M
    J Natl Cancer Inst; 2011 Nov; 103(22):1676-85. PubMed ID: 22021665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
    Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    Alfaiate D; Clément S; Gomes D; Goossens N; Negro F
    J Hepatol; 2020 Sep; 73(3):533-539. PubMed ID: 32151618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.
    Poh Z; Goh BB; Chang PE; Tan CK
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):638-43. PubMed ID: 25831135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers.
    Liu CJ; Chen BF; Chen PJ; Lai MY; Huang WL; Kao JH; Chen DS
    J Infect Dis; 2006 May; 193(9):1258-65. PubMed ID: 16586363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area.
    Yin J; Zhang H; Li C; Gao C; He Y; Zhai Y; Zhang P; Xu L; Tan X; Chen J; Cheng S; Schaefer S; Cao G
    Carcinogenesis; 2008 Sep; 29(9):1685-91. PubMed ID: 18192693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China.
    Ding X; Mizokami M; Yao G; Xu B; Orito E; Ueda R; Nakanishi M
    Intervirology; 2001; 44(1):43-7. PubMed ID: 11223719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance.
    Mak LY; Wong DK; Pollicino T; Raimondo G; Hollinger FB; Yuen MF
    J Hepatol; 2020 Oct; 73(4):952-964. PubMed ID: 32504662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
    Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
    Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 22-year experience at a single center.
    Bae SK; Akamatsu N; Ichida A; Maki H; Nishioka Y; Kawahara T; Hoshikawa M; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Arita J; Kaneko J; Tamura S; Hasegawa K
    Biosci Trends; 2021 Jan; 14(6):443-449. PubMed ID: 33239499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study.
    McMahon BJ; Nolen LD; Snowball M; Homan C; Negus S; Roik E; Spradling PR; Bruden D
    Hepatology; 2021 Dec; 74(6):2965-2973. PubMed ID: 34292609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma.
    Bayliss J; Lim L; Thompson AJ; Desmond P; Angus P; Locarnini S; Revill PA
    J Hepatol; 2013 Nov; 59(5):1022-8. PubMed ID: 23811301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.
    Thiele M; Gluud LL; Fialla AD; Dahl EK; Krag A
    PLoS One; 2014; 9(9):e107177. PubMed ID: 25225801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B virus subgenotype A1 predominates in liver disease patients from Kerala, India.
    Gopalakrishnan D; Keyter M; Shenoy KT; Leena KB; Thayumanavan L; Thomas V; Vinayakumar K; Panackel C; Korah AT; Nair R; Kramvis A
    World J Gastroenterol; 2013 Dec; 19(48):9294-306. PubMed ID: 24409056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
    J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand.
    Sugauchi F; Chutaputti A; Orito E; Kato H; Suzuki S; Ueda R; Mizokami M
    J Gastroenterol Hepatol; 2002 Jun; 17(6):671-6. PubMed ID: 12100612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.